Mersana Therapeutics Highlighted (UPLIFT) Clinical Trial Results of Upifitamab Rilsodotin for Platinum-Resistant Ovarian Cancer
Shots:
- The (UPLIFT) clinical trial evaluating upifitamab rilsodotin (UpRi) in 268 patients with Pt-resistant ovarian cancer with one to four prior treatment regimens
- The trial failed to meet its 1EPs. As of data cut off May 2023 in NaPi2b-positive, ORR (15.6%) in investigator assessment & 16.3% in IRR assessment; PR (14.2% & 11.3%); CR (1.4% & 5.0%); m-DoR (7.4mos. & not reached)
- Among the total population in both assessments, ORR (13.1% & 13.1%); PR (11.9% & 9.0%); CR (1.1% & 4.1%), m-DoR (7.4 & 10.7mos.) & the safety and tolerability were consistent with prior disclosures. The company plans to share efficacy and safety data with the medical and scientific community
Ref: Mersana | Image: Mersana
Related News:- Mersana Therapeutics Reports US FDA’s Partial Clinical Hold on New Patient Enrollment of UpRi for Platinum-Sensitive Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
